Providers and patients still awaiting benefits from boost in generic approvals
Start adding items to your reading lists:
Create your account
Save this item to:
This item has been saved to your reading list.
Senior Manager, Health Research Institute, PwC USOctober 18, 2019
Generic drug companies are benefiting from record numbers of generic drug approvals, but there’s little evidence the approvals are resulting in lower prices or greater availability of drugs experiencing shortages, according to a new study published in JAMA Network Open.
After looking at 1,832 generics approved between July 2016 and December 2018, the study found that, while the FDA’s package of reforms has led to record approvals, it hasn't resulted in a significant increase in generic competition for drugs without adequate competition, nor a decrease in shortages compared with historical baselines.
HRI impact analysis
For healthcare providers and insurers, the lack of sufficient new generic competition may provide increased incentives for them to disrupt the generic market themselves. For example, some hospital systems have teamed up to make drugs that are chronically in shortage situations.
The new research likely is indicative not of a failing by regulators, but of the difficulty of using generic competition as a means of controlling for cost. While generic approvals may be increasing, most approvals likely would have occurred anyway, such as for high-dollar-value drugs coming off patent. For some approved drugs, competition may already exist. According to the study, 79.6 percent of all generic approvals were for drugs with more than three marketed competitors at launch.
Other research published by the Association for Accessible Medicines, the generic drug trade group, offers further insight into why generics may not be a panacea for drug prices. Of the 729 generic drugs approved in 2018, just 551 are actively marketed. Twenty-nine percent of the 2,136 generics approved in 2016-18 had not been marketed.